ArticleHormones (Athens, Greece)2025
Nationwide web survey on implementing the 2023 ETA guidelines for second-line management thyroid nodules with atypia of undetermined significance.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- De-escalation implementation in low-risk papillary thyroid cancer: a nationwide survey.Endocrine connections · 2026Article
- Promise and pitfalls of AI chatbots in complex decision-making for thyroid nodules and papillary thyroid cancer.European thyroid journal · 2026Article
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid nodules affect up to 70% of adults undergoing ultrasonography. The European Thyroid Association (ETA) recently issued high-quality guidelines outlining management options. However, their implementation in routine practice remains uncertain. This study examined guideline adoption and barriers, focusing on nodules with atypia of undetermined significance (AUS), a particularly challenging cytological category.
methodsFrom November 2023 to April 2024, members of the Hellenic Endocrine Society (HES) participated in a web-based survey concerning management of a 2.5 cm thyroid nodule with fine-needle aspiration (FNA) cytology results of AUS. The scenario varied based on the nodule's sonographic risk, namely, as intermediate (EU-TIRADS 4) or high (EU-TIRADS 5). The questionnaire also collected demographic information and inquired about reasons for non-adherence to the guidelines.
resultsThe response rate was 25%. For an EU-TIRADS 4 nodule, 61% chose to repeat FNA, whereas only 23% would repeat FNA for an EU-TIRADS 5 nodule, despite the 2023 ETA guidelines recommending this approach as the next step in both cases. More experienced endocrinologists were less likely to opt for repeat FNA and more likely to choose total thyroidectomy in the first scenario, whereas experience did not influence preferences in the second scenario. Reasons for non-compliance were skepticism regarding the recommendations, limited access to reliable neck ultrasonography, and molecular testing, and a shortage of high-volume surgeons.
conclusionsGreek endocrinologists deviate from the 2023 ETA guidelines for the management of thyroid nodules with AUS cytology in daily clinical practice. These findings highlight the need for targeted educational strategies and enhancement of clinical infrastructure in Greece.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.